Palomar Medical Announces Stock Repurchase Program
17 11월 2012 - 12:02AM
Palomar Medical Technologies, Inc. (Nasdaq:PMTI), a global leader
in laser and other light-based systems for aesthetic treatments,
today announced its Board of Directors has approved a Stock
Repurchase Program under which the Company is authorized to
repurchase up to one million five hundred thousand shares of its
common stock. This program is authorized to begin immediately. Any
stock repurchases will be made from time to time through open
market purchases, block purchases and other transactions complying
with the Securities and Exchange Commission's Rule 10b-18. The
timing and actual number of shares purchased will depend on a
variety of factors such as price, corporate and regulatory
requirements, alternative investment opportunities and other market
conditions. Stock repurchases under this program, if any, will be
made using the Company's cash resources, and may be commenced or
suspended at any time or from time to time at management's
discretion without prior notice.
About Palomar Medical Technologies, Inc.:
Palomar designs, produces and sells the most advanced cosmetic
lasers and intense pulsed light (IPL) systems to dramatically
improve the appearance of women's and men's skin. For over 15
years, Palomar has pioneered the science of using lasers and light
to improve appearances. As the industry's technology leader,
Palomar has invested in creating cosmetic laser and IPL systems
that put real value in the hands of physicians and other
professionals to benefit consumers. Thousands of physicians
worldwide trust and depend on Palomar technology to not only
introduce new aesthetic treatments such as advanced laser hair
removal, laser liposuction, skin resurfacing, acne, laser
treatments for scars, wrinkle treatment, stretch marks (striae),
and photofacials for pigmented and vascular lesions, but to also
make them robust, faster, more powerful, and more comfortable for
those being treated. In June 2009, Palomar became the first
company to receive a 510(k) over-the-counter ("OTC") clearance from
the FDA for a new, patented, home-use, laser device for the
treatment of fine lines and wrinkles around the eyes (periorbital
wrinkles). This OTC clearance allows the PaloVia® Skin Renewing
Laser® to be marketed and sold directly to consumers without a
prescription.
For more information on Palomar and its products, visit
Palomar's website at palomarmedical.com for professional products
or palovia.com for consumer products. To continue receiving the
most up-to-date information and latest news on Palomar as it
happens, sign up to receive automatic e-mail alerts by going to the
About Palomar/Investors section of the website.
Statements in this press release regarding the Company's
intention to repurchase shares of its common stock from time to
time under the Stock Repurchase Program are forward-looking
statements. There are a number of important factors that could
cause actual events to differ materially from those suggested or
indicated by such forward-looking statements. These include, among
others, the market price of the Company's stock prevailing from
time to time, the nature of other investment opportunities
presented to the Company from time to time, the Company's cash flow
operations, general economic conditions, and other factors
identified in the Company's most recent Annual Report on Form 10-K
and Quarterly Report on Form 10-Q filed with the SEC.
CONTACT: Kerry McAnistan
Investor Relations Assistant
Palomar Medical Technologies, Inc.
781-993-2411
ir@palomarmedical.com
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024